Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
Regeneron's Pasatru shows sustained efficacy in halting new bone growth and reducing flare-ups in adults with FOP in an 84-week trial.
Stocks · News reference
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru™ (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
Bayer announced FDA acceptance of a supplemental new drug application for Kerendia (finerenone) to treat chronic kidney disease in non-diabetic patients. The approval is based on positive phase III FIND-CKD trial data showing the drug significantly delayed kidney disease progression and reduced cardiovascular-kidney events. This expansion broadens Kerendia's addressable market and strengthens Bayer's cardiovascular and renal portfolio, with the drug already approved for diabetic CKD and heart failure in multiple markets.